CADTH Canadian Drug Expert Committee recommendation: Apomorphine hydrochloride (Kynmobi -- Sunovion Pharmaceuticals Canada inc.) indication : the acute, intermittent treatment of "OFF" episodes in patients with Parkinson disease (PD)
APO SL has a Health Canada indication for the acute, intermittent treatment of OFF episodes in patients with PD. APO is a non-ergot dopamine agonist. The precise mechanism of action of APO SL as a treatment for OFF episodes associated with PD is unknown, although it is believed to be due to stimulat...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
February 2021, 2021
|
| Edition: | Version: 1.0 |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | APO SL has a Health Canada indication for the acute, intermittent treatment of OFF episodes in patients with PD. APO is a non-ergot dopamine agonist. The precise mechanism of action of APO SL as a treatment for OFF episodes associated with PD is unknown, although it is believed to be due to stimulation of post-synaptic dopamine D2-type receptors within the caudate-putamen in the brain. APO SL is available as soluble film containing 10 mg, 15 mg, 20 mg, 25 mg, or 30 mg APO per film |
|---|---|
| Item Description: | "Final." |
| Physical Description: | 1 PDF file (9 pages) |